Merck & Co. (MRK) has delivered better-than-expected Q3 results driven by top-line growth, which was aided by strong performance across Oncology, Vaccines and …
Merck (MRK) and Ridgeback Biotherapeutics announced that the former has submitted an Emergency Use Authorization (EUA) application to the U.S.
Women’s health company Organon (OGN), which was spun-off from Merck (MRK), has completed the acquisition of commercial-stage medical device company Alydia Health. The …
Merck (MRK) reported disappointing first quarter results on Thursday with sales of $12.1 billion falling 1%, excluding the impact of currency fluctuations.
Nektar Therapeutics reported a better-than-expected loss in the fourth quarter but lagged analysts’ expectations for revenues. Shares of the biopharmaceutical company dropped almost …
Merck & Company agreed to snap up Pandion Therapeutics, a clinical-stage biotechnology company, in a deal worth $1.85 billion.
Merck & Co. has decided to stop the development of its two COVID-19 vaccine candidates following “inferior” immune responses.
Merck & Co has entered into a definitive agreement to snap up all outstanding shares of VelosBio for $2.75 billion in cash, in …
Sanofi (SNYNF) has entered into an agreement with Merck to conduct a Phase 2 clinical trial to evaluate the safety, pharmacokinetics, and preliminary …
With COVID-19 cases continuing to surge, the attention of the whole world is currently on pharma companies developing potential treatments and vaccines for …
